Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
暂无分享,去创建一个
G. Fabbrocini | M. Napolitano | K. Peris | A. Balato | G. Girolomoni | S. Ferrucci | M. Romanelli | G. Babino | A. Parodi | S. Ribero | M. Fargnoli | A. Marzano | A. Bertoldi | A. Chiricozzi | M. Ortoncelli | M. Rossi | R. Balestri | L. Stingeni | D. Schena | N. Gori | A. Pitino | Giovanni Palazzo | Michele Pellegrino | Giovanni Tripepi | F. Antonelli
[1] P. Ghislain,et al. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults , 2023, Advances in therapy.
[2] K. Peris,et al. Successful response of upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab. , 2023, Clinical and experimental dermatology.
[3] A. Deodhar,et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis , 2023, RMD Open.
[4] A. Costanzo,et al. Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study , 2023, Dermatology and Therapy.
[5] M. Schuttelaar,et al. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry , 2023, Contact dermatitis.
[6] G. Fabbrocini,et al. Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience. , 2022, Clinical and experimental dermatology.
[7] G. Fabbrocini,et al. Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study , 2022, Drugs in R&D.
[8] K. Peris,et al. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis , 2022, Expert opinion on drug metabolism & toxicology.
[9] J. Thyssen,et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis , 2022, JAMA dermatology.
[10] K. Peris,et al. Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients , 2021, Dermatology.
[11] A. Costanzo,et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis , 2021, JAMA dermatology.
[12] G. Argenziano,et al. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study , 2021, American Journal of Clinical Dermatology.
[13] K. Peris,et al. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy , 2021, Dermatology.
[14] C. Flohr,et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis , 2020, Allergy.
[15] K. Peris,et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* , 2020, The British journal of dermatology.
[16] G. Dal Bello,et al. Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients , 2020, Dermatologic therapy.
[17] J. Silverberg,et al. Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial. , 2019, Journal of Allergy and Clinical Immunology.
[18] T. Bieber,et al. Atopic dermatitis , 2018, Nature Reviews Disease Primers.
[19] D. Margolis,et al. Epidemiology of atopic dermatitis in adults: Results from an international survey , 2018, Allergy.
[20] M. Cork,et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) , 2018, The British journal of dermatology.
[21] E. Lopez-Gonzalez,et al. Determinants of Under-Reporting of Adverse Drug Reactions , 2009, Drug safety.
[22] L. Hazell,et al. Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.